Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

Rhea-AI Summary

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will release its Q4 and full year 2023 financial and operating results on February 20, 2024. A conference call will be held to discuss the results, and a live webcast and replay will be available on the company's website.

SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading.

Halozyme will host a conference call on Tuesday, February 20, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871904.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE^® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including Hylenex® and XYOSTED^® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Samantha Gaspar
Teneo
617-877-9710
samantha.gaspar@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-302058060.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme release its Q4 and full year 2023 financial and operating results?

Halozyme will release its Q4 and full year 2023 financial and operating results on February 20, 2024.

What is the ticker symbol for Halozyme Therapeutics, Inc.?

The ticker symbol for Halozyme Therapeutics, Inc. is HALO.

When is the conference call to discuss the results?

The conference call to discuss the results will be held on February 20, 2024 at 1:30 p.m. PT/4:30 p.m. ET.

Where can I access the live webcast and replay of the conference call?

The live webcast and replay of the conference call will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.